Browsing by Author "Shyamali"

Now showing 1 - 2 of 2

Leishmania Proteomics: Insight into Diagnostics and Vaccine Development
(Springer Nature, 2024) Dharmendra Kumar Maurya; Shyamali; Shyam Lal Mudavath; Shyam Sundar; Om Prakash Singh
Visceral leishmaniasis (VL), a life-threatening parasitic disease in the Indian subcontinent, is caused by the protozoan parasites-Leishmania donovani and transmitted by the bite of the Phlebotomus sand fly. These parasites have adopted many invasion mechanisms to survive the host’s direct immune responses and established themselves in the host cells. Although efforts have been made to develop sensitive biomarkers for diagnosis and effective vaccines for VL treat-ment, we still need to achieve these goals with great success. Advances in various proteomic platforms have allowed us to identify large numbers of surface and cytosolic proteins from mixed stages of the Leishmania life cycle, which can be manipulated as a diagnostic marker or can be used as vaccine candidates. In this review, we highlight the proteins in amastigote and promastigote forms of Leish-mania parasite and discuss their potential implications in future diagnostic and vaccine development. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2023.
Vaccine human clinical trial
(Elsevier, 2022) Bhawana Singh; Shyamali; Dharmendra Kumar Maurya; Rajiv Kumar; Shashi Bhushan Chauhan; Shyam Lal Mudavath; Ram Niwas Meena; Shyam Sundar; Om Prakash Singh
Globally incidence of infectious diseases has declined over the past decades, but still, they continue to have major public health and economic costs. Treatment of infectious diseases is complicated by patients’ late presentation at an advanced stage of their illness. Other challenges include high cost of treatment (drug and hospitalization) and increasing drug resistance. Because of this lack of effective, affordable, minimally toxic drug therapies, an effective vaccine to control infectious diseases is needed. The development of a prophylactic vaccine would prove to be the most effective strategy of disease control and one of the most cost-effective investments in the health sector. However, each newly developed vaccine needs to be evaluated for safety, immunogenicity, and prophylactic efficacy in humans before it is licensed for public use. In this book chapter, we discuss the key elements that should be considered to conduct the vaccine clinical trials against infectious diseases including COVID-19. © 2022 Elsevier Inc. All rights reserved.